Daphne L. Taylor's most recent trade in Aptevo Therapeutics Inc was a trade of 2 Common Stock done . Disclosure was reported to the exchange on March 2, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 2 | 17 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 2 | 2 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 1 | 0 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2025 | 1 | 18 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 158 | 0 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2024 | 158 | 576 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 8,550 | 8,550 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 3,667 | 16,827 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 3,667 | 7,333 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 1,584 | 1,583 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2024 | 1,584 | 18,411 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Taylor Daphne L. | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 792 | 0 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 792 | 13,160 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 6,945 | 6,944 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 6,945 | 12,368 (0%) | 0% | - | Common Stock | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 11,000 | 11,000 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 1,583 | 3,167 | - | - | Restricted Stock Unit | |
Aptevo Therapeutics Inc | Daphne L. Taylor | SVP, CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2023 | 1,583 | 5,423 (0%) | 0% | - | Common Stock |